A Late Arriving but Welcome Advance in Sarcoma Therapy

This editorial reflects on a landmark phase 3 trial demonstrating the survival benefit of doxorubicin combined with trabectedin in patients with leiomyosarcoma a soft tissue sarcoma subtype. The author contextualizes decades of failed attempts to improve outcomes beyond single agent doxorubicin and critiques historical trial limitations, such as histologic diversity and underpowering. The recent LMS-04 trial by the French Sarcoma Group represents a turning point, showing significant survival gains. The article also addresses missed opportunities due to regulatory delays and commercial disincentives, calling for policy and reimbursement reform to support further research in sarcoma subtypes.

This editorial reflects on a landmark phase 3 trial demonstrating the survival benefit of doxorubicin combined with trabectedin in patients with leiomyosarcoma a soft tissue sarcoma subtype. The author contextualizes decades of failed attempts to improve outcomes beyond single agent doxorubicin and critiques historical trial limitations, such as histologic diversity and underpowering. The recent LMS-04 trial by the French Sarcoma Group represents a turning point, showing significant survival gains. The article also addresses missed opportunities due to regulatory delays and commercial disincentives, calling for policy and reimbursement reform to support further research in sarcoma subtypes.